Literature DB >> 22517769

Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.

Michael Camilleri1, Maria Vazquez-Roque, Johanna Iturrino, Amy Boldingh, Duane Burton, Sanna McKinzie, Banny S Wong, Archana S Rao, Enda Kenny, Maria Månsson, Alan R Zinsmeister.   

Abstract

The glucagon-like peptide 1 (GLP-1) analog ROSE-010 reduced pain during acute exacerbations of irritable bowel syndrome (IBS). Our objective was to assess effects of ROSE-010 on several gastrointestinal (GI) motor and bowel functions in constipation-predominant IBS (IBS-C). In a single-center, randomized, parallel-group, double-blind, placebo-controlled, dose-response study, we evaluated safety, pharmacodynamics, and pharmacokinetics in female patients with IBS-C. ROSE-010 (30, 100, or 300 μg sc) or matching placebo was administered once daily for 3 consecutive days and on 1 day 2-10 days later. We measured GI and colonic transit by validated scintigraphy and gastric volumes by single-photon emission computed tomography. The primary end points were half time of gastric emptying of solids, colonic transit geometric center at 24 h, and gastric accommodation volume. Analysis included intent-to-treat principle, analysis of covariance (with body mass index as covariate), and Dunnett-Hsu test for multiple comparisons. Exposure to ROSE-010 was approximately dose-proportional across the dose range tested. Demographic data in four treatment groups of female IBS-C patients (total 46) were not different. Gastric emptying was significantly retarded by 100 and 300 μg of ROSE-010. There were no significant effects of ROSE-010 on gastric volumes, small bowel or colonic transit at 24 h, or bowel functions. The 30- and 100-μg doses accelerated colonic transit at 48 h. Adverse effects were nausea (P < 0.001 vs. placebo) and vomiting (P = 0.008 vs. placebo). Laboratory safety results were not clinically significant. In IBS-C, ROSE-010 delayed gastric emptying of solids but did not retard colonic transit or alter gastric accommodation; the accelerated colonic transit at 48 h with 30 and 100 μg of ROSE-010 suggests potential for relief of constipation in IBS-C.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22517769     DOI: 10.1152/ajpgi.00076.2012

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  14 in total

1.  Identification of expression and function of the glucagon-like peptide-1 receptor in colonic smooth muscle.

Authors:  Alexander T May; Molly S Crowe; Bryan A Blakeney; Sunila Mahavadi; Hongxia Wang; John R Grider; Karnam S Murthy
Journal:  Peptides       Date:  2018-11-30       Impact factor: 3.750

2.  Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial.

Authors:  Anne-Marie Langmach Wegeberg; Christian Stevns Hansen; Adam D Farmer; Jesper Scott Karmisholt; Asbjorn M Drewes; Poul Erik Jakobsen; Birgitte Brock; Christina Brock
Journal:  United European Gastroenterol J       Date:  2020-05-09       Impact factor: 4.623

Review 3.  Recent advances in pharmacological treatment of irritable bowel syndrome.

Authors:  Georgia Lazaraki; Grigoris Chatzimavroudis; Panagiotis Katsinelos
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 4.  Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.

Authors:  Khaled A Jadallah; Susan M Kullab; David S Sanders
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

5.  Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations.

Authors:  Alan R Zinsmeister; Duane Burton; Michael Camilleri
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

Review 6.  New and Investigational Agents for Irritable Bowel Syndrome.

Authors:  Akhilesh Wadhwa; Michael Camilleri; Madhusudan Grover
Journal:  Curr Gastroenterol Rep       Date:  2015-12

Review 7.  Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.

Authors:  Michael Camilleri
Journal:  J Clin Invest       Date:  2013-10-01       Impact factor: 14.808

Review 8.  Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms.

Authors:  Michael Camilleri
Journal:  J Physiol       Date:  2014-03-24       Impact factor: 5.182

9.  Use of Molecular Imaging in Clinical Drug Development: a Systematic Review.

Authors:  Hyeomin Son; Kyungho Jang; Heechan Lee; Sang Eun Kim; Keon Wook Kang; Howard Lee
Journal:  Nucl Med Mol Imaging       Date:  2019-04-16

10.  Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine.

Authors:  Qian Zhang; Xinhua Xiao; Ming Li; Wenhui Li; Miao Yu; Huabing Zhang; Fan Ping; Zhixin Wang; Jia Zheng
Journal:  BMC Complement Altern Med       Date:  2014-06-09       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.